CN105949189A - 一种用于治疗乳腺癌的帕博西尼的制备方法 - Google Patents
一种用于治疗乳腺癌的帕博西尼的制备方法 Download PDFInfo
- Publication number
- CN105949189A CN105949189A CN201610398962.6A CN201610398962A CN105949189A CN 105949189 A CN105949189 A CN 105949189A CN 201610398962 A CN201610398962 A CN 201610398962A CN 105949189 A CN105949189 A CN 105949189A
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyrimidine
- amino
- piperazinyl
- cyclopenta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398962.6A CN105949189B (zh) | 2016-06-05 | 2016-06-05 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610398962.6A CN105949189B (zh) | 2016-06-05 | 2016-06-05 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105949189A true CN105949189A (zh) | 2016-09-21 |
CN105949189B CN105949189B (zh) | 2017-09-22 |
Family
ID=56907769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610398962.6A Active CN105949189B (zh) | 2016-06-05 | 2016-06-05 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105949189B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017067506A1 (zh) * | 2015-10-22 | 2017-04-27 | 苏州晶云药物科技有限公司 | 帕博西尼的新晶型 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020025968A1 (en) * | 1998-04-15 | 2002-02-28 | Rifat Pamukcu | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives |
WO2008032157A2 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
CN102295643A (zh) * | 2002-01-22 | 2011-12-28 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
CN105541832A (zh) * | 2015-12-15 | 2016-05-04 | 南京艾德凯腾生物医药有限责任公司 | 一种羟乙基磺酸盐帕布昔利布的制备方法 |
-
2016
- 2016-06-05 CN CN201610398962.6A patent/CN105949189B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020025968A1 (en) * | 1998-04-15 | 2002-02-28 | Rifat Pamukcu | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives |
CN102295643A (zh) * | 2002-01-22 | 2011-12-28 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
WO2008032157A2 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
CN105541832A (zh) * | 2015-12-15 | 2016-05-04 | 南京艾德凯腾生物医药有限责任公司 | 一种羟乙基磺酸盐帕布昔利布的制备方法 |
Non-Patent Citations (3)
Title |
---|
ANNA-MARIE LORD 等: "Design, Synthesis, and Evaluation in Vitro of Quinoline-8-carboxamides, a New Class of Poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) Inhibitor", 《J. MED. CHEM.》 * |
NAHREN MANUEL MASCARENHAS 等: "Combined Ligand and Structure Based Approaches for Narrowing on the Essential Physicochemical Characteristics for CDK4 Inhibition", 《J. CHEM. INF. MODEL.》 * |
SANJAY S. PALIMKAR 等: "Synthesis of an indole containing KDR kinase inhibitor by tandem Sonogashira coupling-5-endo-dig-cyclization as a key step", 《TETRAHEDRON》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017067506A1 (zh) * | 2015-10-22 | 2017-04-27 | 苏州晶云药物科技有限公司 | 帕博西尼的新晶型 |
Also Published As
Publication number | Publication date |
---|---|
CN105949189B (zh) | 2017-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104496983A (zh) | 一种帕博西尼的制备方法 | |
EP2857393B1 (en) | N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and antitumor application thereof | |
CN105111205B (zh) | 一种帕博西尼的制备方法 | |
CN103554201B (zh) | 一种加米霉素的制备方法 | |
CN104926798A (zh) | 阿法替尼中间体的高纯度制备方法 | |
CN104945332A (zh) | 埃罗替尼的制备方法 | |
CN103087059B (zh) | 一种高纯度盐酸奥普力农的制备方法 | |
CN106008499B (zh) | 一种制备cdk46激酶抑制剂帕博西尼的方法 | |
CN105906622B (zh) | 一种用于治疗乳腺癌的帕博西尼的制备方法 | |
CN104945436B (zh) | 一种米诺膦酸的制备方法 | |
CN105968109B (zh) | 一种制备帕博西尼中间体的方法 | |
CN105949189A (zh) | 一种用于治疗乳腺癌的帕博西尼的制备方法 | |
CN103980188B (zh) | 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法 | |
CN106083844B (zh) | 一种制备抗乳腺癌药物帕博西尼中间体的方法 | |
CN104744537A (zh) | 一种卡培他滨的合成方法 | |
CN103864877A (zh) | 一种醋酸阿比特龙的制备方法 | |
CN113637003B (zh) | 一种制备2-氨基-6-(哌啶-4-酰基)吡啶衍生物的方法 | |
CN108047133A (zh) | 一种喹啉酮类化合物的制备方法 | |
CN103896889B (zh) | 拉帕替尼中间体及其制备方法和应用 | |
CN106279020A (zh) | 一种诺氟沙星d晶型及其制备方法、制剂与应用 | |
CN103351346A (zh) | 盐酸苯达莫司汀杂质hp1的制备方法 | |
CN109369772B (zh) | 一种菲啶类两面针碱衍生物的合成方法及抗肿瘤应用 | |
CN108623599A (zh) | 一种快速合成Ribociclib方法 | |
CN108484617B (zh) | 新型苯并呋喃氮杂萘二酮衍生物及其制备方法 | |
CN105198864B (zh) | 一种环戊基嘧啶化合物的无溶剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Tong Mingqiong Inventor after: Cheng Canling Inventor after: Shang Meihua Inventor before: Tong Mingqiong Inventor before: Wang Xinxing Inventor before: Liu Enhui |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210106 Address after: 102200 423, 4 / F, block a, Xinhua future city building, 175 Litang Road, Changping District, Beijing Patentee after: Li Qiannan Address before: 276000 No.30, jinqueshan Road, Lanshan District, Linyi City, Shandong Province Patentee before: Tong Mingqiong |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210615 Address after: Room 414, building 5, 257 Hushu South Road, Gongshu District, Hangzhou, Zhejiang 310000 Patentee after: Hangzhou Jinbo Pharmaceutical Technology Co.,Ltd. Address before: 102200 423, 4 / F, block a, Xinhua future city building, 175 Litang Road, Changping District, Beijing Patentee before: Li Qiannan |